Arterial hypertension in liver transplant recipients is diagnosed in approximately 36-100% of cases. The development of arterial hypertension is considered to be the consequence not only of changes in cardiovascular system associated with liver transplantation but also of immunosuppressive treatment and complex physiopathological processes affecting the hormonal system and vascular endothelium. Introduction of ambulatory blood pressure monitoring (ABPM) in liver transplant recipients has contributed to enrichment of the amount of data available on blood pressure physiopathology and epidemiology in this population. In view of specific physiopathological mechanisms engaged in hypertension development, antihypertensive treatment in liver transplant recipients requires a special approach.